Results: Using network pharmacology analysis and molecular docking, anwuligan was found to be a major active ingredient in BaoHeWan, potentially acting by binding to CTNNB1
This pattern indicates that AOD-9604 produces minimal additional symptom burden beyond what would be expected in the absence of treatment
Common Mild Reactions Local irritation where the peptide was injected (minor redness or tenderness) Occasional dizziness or fatigue shortly after use Typically mild and short-lived Potential Risks Not FDA-approved for Lyme disease or any other condition Contraindicated in active cancer due to its angiogenesis-promoting properties Should be avoided during pregnancy or breastfeeding Take Precautions with Medical Guidance Since its administered via injection and isnt regulated for Lyme treatment, a professional Lyme disease expert should guide your dosing
Most consumer coverage quotes one without naming which, which makes cross-trial comparisons against tirzepatide's headlines noisier than they need to be
They are different complications, but can sometimes occur together
Rodriguez Milla MA, Maurer A, Rodriguez Huete A, Gustafson JP